Autor: "Reinisch, Walter" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Autorzy:: Olivera PA; IBD Unit, Gastroenterology Section, Department of Internal Medicine, Centro de Educación Médica e Investigación Clínica (CEMIC), Buenos Aires, Argentina.; Zane Cohen Centre for Digestive Diseases, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Lasa JS; IBD Unit, Gastroenterology Section, Department of Internal Medicine, Centro de Educación Médica e Investigación Clínica (CEMIC), Buenos Aires, Argentina.; Gastroenterology Department, Hospital Británico de Buenos Aires, Argentina.
Zubiaurre I; Gastroenterology Department, Hospital Británico de Buenos Aires, Argentina.
Jairath V; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.; Alimentiv Inc., London, ON, Canada.
Abreu MT; Department of Medicine, Division of Gastroenterology, Crohn's and Colitis Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Rubin DT; University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Magro F; Department of Pharmacology & Therapeutics; CINTESIS, Faculty of Medicine University of Porto, and Department of Gastroenterology, Hospital de São João, Porto, Portugal.
Rahier JF; Department of Gastroenterology and Hepatology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
Danese S; Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
Rabaud C; Department of Infectious Disease, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.
Peyrin-Biroulet L; INSERM NGERE and Department of Hepatogastroenterology, Nancy University Hospital, Lorraine University, Vandoeuvre-lés-Nancy, France.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2023 Mar 18; Vol. 17 (2), pp. 199-210.
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:: Opportunistic Infections*/epidemiology
Opportunistic Infections*/etiology
Inflammatory Bowel Diseases*/complications
Inflammatory Bowel Diseases*/drug therapy
Adult ; Humans ; Randomized Controlled Trials as Topic ; Incidence

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Time to Endorse A Sensitive Method for Scoring Endoscopic Activity of Ulcerative Colitis in Clinical Research.
Autorzy:: Narula N; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Merat S; Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.; Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Liu D; Protagonist Therapeutics, Newark, CA, USA.
Pugatch D; Protagonist Therapeutics, Newark, CA, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2023 Mar 18; Vol. 17 (2), pp. 302-304.
Typ publikacji:: Journal Article
MeSH Terms:: Colitis, Ulcerative*/diagnosis
Colitis, Ulcerative*/drug therapy
Humans ; Severity of Illness Index ; Endoscopy ; Colonoscopy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD].
Autorzy:: Narula N; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Pray C; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marshall JK; Department of Medicine and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton, ON, Canada.
Daperno M; Department of Internal Medicine, AO Ordine Mauriziano di Torino, Turin, Italy.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Dulai PS; Division of Gastroenterology, Northwestern University, Chicago, IL,USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Aug 04; Vol. 16 (7), pp. 1011-1019.
Typ publikacji:: Journal Article
MeSH Terms:: Crohn Disease*/diagnostic imaging
Crohn Disease*/drug therapy
Endoscopy, Gastrointestinal ; Humans ; Prognosis ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
Autorzy:: Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, M cmaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Oct 07; Vol. 15 (10), pp. 1649-1657.
Typ publikacji:: Journal Article
MeSH Terms:: Remission Induction*
Constriction, Pathologic/*drug therapy
Crohn Disease/*drug therapy
Adult ; Azathioprine/therapeutic use ; Clinical Trials as Topic ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Infliximab/therapeutic use ; Male ; Ustekinumab/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
Autorzy:: Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Buffone E; Department of Medicine, McGill University, Montreal, QC, Canada.
Lee SJ; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton ON, Canada.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Jul 05; Vol. 15 (7), pp. 1114-1119.
Typ publikacji:: Journal Article
MeSH Terms:: Patient Reported Outcome Measures*
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adult ; Colonoscopy ; Female ; Humans ; Male ; Prognosis ; Remission Induction

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
Autorzy:: Agrawal M; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Brenner EJ; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
Zhang X; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
Colombel JF; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kappelman MD; University of North Carolina, Department of Pediatrics, Chapel Hill, NC, USA.
Ungaro RC; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gearry RB
Kalpan GG
Kissous-Hunt M
Lewis JD
Ng SC
Rahier JF
Reinisch W
Ruemmele FM
Steinwurz F
Underwood FE; Pokaż więcej
Corporate Authors:: SECURE-IBD Advisory Committee including
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 May 04; Vol. 15 (5), pp. 860-863.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19/*epidemiology
Inflammatory Bowel Diseases/*drug therapy
Practice Patterns, Physicians'/*statistics & numerical data
Adult ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Female ; Glucocorticoids/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Inflammatory Bowel Diseases/epidemiology ; Integrins/antagonists & inhibitors ; Male ; Registries ; Tumor Necrosis Factor Inhibitors/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials.
Autorzy:: Narula N; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Wong ECL; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Marshall JK; Department of Medicine [Division of Gastroenterology] and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reinisch W; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Mar 05; Vol. 15 (3), pp. 462-470.
Typ publikacji:: Journal Article
MeSH Terms:: Remission Induction*
Crohn Disease/*drug therapy
Feces/*chemistry
Leukocyte L1 Antigen Complex/*analysis
Adult ; Biomarkers/analysis ; Endoscopy, Gastrointestinal ; Female ; Gastrointestinal Agents/therapeutic use ; Humans ; Male ; Randomized Controlled Trials as Topic ; Ustekinumab/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Autorzy:: Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; Department of Gastrointestinal and Liver Services, Royal London Hospital, Barts Health NHS Trust, London, UK.
Teich N; Innere Medizin/Gastroenterologie, Internistische Gemeinschaftspraxis, Leipzig, Germany.
Lindgren S; Department of Gastroenterology, Lund University, Malmo, Sweden.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Flynn HA; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Huyck S; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Stryszak P; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Yao R; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Philip G; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1148-1157.
Typ publikacji:: Comparative Study; Journal Article; Observational Study
MeSH Terms:: Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Adult ; Europe ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Infections/chemically induced ; Infliximab/adverse effects ; Male ; Product Surveillance, Postmarketing ; Prospective Studies ; Registries

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.
Autorzy:: Hanauer S; Northwestern University, Digestive Health Centre, Chicago, IL, USA.
Sandborn WJ; University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, NY, USA.
Vermeire S; University Hospital Leuven, Gastroenterology, Leuven, Belgium.
Petersson J; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Kligys K; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Zhou Q; AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, IL, USA.
Lazar A; AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
Reinisch W; Medical University of Vienna, Department for Gastroenterology and Hepatology, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1227-1233.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Colitis, Ulcerative/*drug therapy
Adult ; Aged ; Biomarkers/blood ; Blood Proteins/analysis ; C-Reactive Protein/analysis ; Colitis, Ulcerative/pathology ; Erythrocyte Count ; Female ; Hematocrit ; Hemoglobins/analysis ; Humans ; Intestinal Mucosa/pathology ; Male ; Middle Aged ; Platelet Count ; Quality of Life ; Serum Albumin/analysis ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
Autorzy:: Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Gibson PR; Monash University and Alfred Hospital, Melbourne, VIC, Australia.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Strauss R; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Johanns J; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Padgett L; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Adedokun OJ; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Collins J; Oregon Health & Science University and Portland VA Medical Center, Portland, OR, USA.
Rutgeerts P; Division of Gastroenterology and Hepatology, University of Leuven, Gasthuisberg, Leuven, Belgium.
Tarabar D; Department of Gastroenterology, Military Medical Academy, Belgrade, Serbia.
Marano C; Immunology, Janssen Research & Development, LLC., Spring House, PA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Aug 29; Vol. 12 (9), pp. 1053-1066.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Adolescent ; Adult ; Aged ; Cohort Studies ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
Autorzy:: Reinisch W; Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Hung K; Pfizer Inc, Precision Medicine, Cambridge, MA, USA.
Hassan-Zahraee M; Early Clinical R&D | Precision Medicine, Pfizer Inc, Cambridge, MA, USA.
Cataldi F; Cataldi Research Solutions, Beverly, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Aug 22; Vol. 12 (suppl_2), pp. S669-S677.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Gastrointestinal Agents/*therapeutic use
Immunoglobulins/*metabolism
Inflammatory Bowel Diseases/*drug therapy
Intercellular Adhesion Molecule-1/*metabolism
Mucoproteins/*metabolism
Phosphorothioate Oligonucleotides/*therapeutic use
Animals ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cell Adhesion Molecules ; Cell Movement ; Humans ; Immunoglobulins/immunology ; Intercellular Adhesion Molecule-1/immunology ; Leukocytes/immunology ; Molecular Targeted Therapy ; Mucoproteins/antagonists & inhibitors ; Mucoproteins/immunology ; Pouchitis/drug therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy:: Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 510.
Typ publikacji:: Journal Article; Published Erratum

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
Autorzy:: D'Haens G; Academic Medical Center, Amsterdam, The Netherlands.
Vermeire S; Leuven University Hospital, Leuven, Belgium.
Vogelsang H; Medical University of Vienna, Vienna, Austria.
Allez M; Hôpital Saint-Louis, Université Paris Diderot, Paris, France.
Desreumaux P; University of Lille, Lille, France.
Van Gossum A; Erasme Hospital, Free University of Brussels, Brussels, Belgium.
Sandborn WJ; University of California San Diego, La Jolla, CA, USA.
Baumgart DC; Charité Medical School, Humboldt-University of Berlin, Berlin, Germany.
Ransohoff RM; Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.
Comer GM; Kimberton Drug Development Consulting, Phoenixville, PA, USA.
Ahmad A; Pfizer, Cambridge, MA, USA.
Cataldi F; Pfizer, Cambridge, MA, USA.
Cheng J; Pfizer, Cambridge, MA, USA.
Clare R; Pfizer, Cambridge, MA, USA.
Gorelick KJ; Pfizer, Cambridge, MA, USA.
Kaminski A; Pfizer, Cambridge, MA, USA.
Pradhan V; Pfizer, Cambridge, MA, USA.
Rivers S; Pfizer, Cambridge, MA, USA.
Sikpi MO; Pfizer, Cambridge, MA, USA.
Zhang Y; Pfizer, Cambridge, MA, USA.
Hassan-Zahraee M; Pfizer, Cambridge, MA, USA.
Reinisch W; Medical University of Vienna, Vienna, Austria.; McMaster University, Hamilton, ON, Canada.
Stuve O; Neurology Section, VA North Texas Health Care System, Dallas, TX, USA.; Southwestern Medical Center, University of Texas, Dallas, TX, USA.; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Germany.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Jan 24; Vol. 12 (2), pp. 188-196.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Central Nervous System/*immunology
Crohn Disease/*immunology
Integrin beta Chains/*metabolism
T-Lymphocytes/*metabolism
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized/pharmacology ; Crohn Disease/blood ; Crohn Disease/cerebrospinal fluid ; Female ; Humans ; Immunologic Surveillance/drug effects ; Immunosuppressive Agents/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/chemically induced ; Lymphocyte Count ; Male ; Middle Aged ; T-Lymphocyte Subsets ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy:: Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Aug 01; Vol. 11 (8), pp. 921-929.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/blood ; Dose-Response Relationship, Drug ; Double-Blind Method ; Feces/chemistry ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Male ; Middle Aged ; Remission Induction/methods ; Serum Albumin/analysis ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Autorzy:: D'Haens G; Department of Gastroenterology, Academic MedicalCenter, Amsterdam, The Netherlands.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Medical University, Vienna, Austria and McMaster University, Hamilton, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Panes J; Department of Gastroenterology, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Ghosh S; Department of Gastroenterology, University of Calgary, Calgary, AB, Canada.
Prantera C; Department of Gastroenterology, A.O. San Camillo Forlanini, Rome, Italy.
Lindgren S; Department of Gastroenterology, Lund University, University Hospital Skane, Malmö, Sweden.
Hommes DW; Centre for Inflammatory Bowel Diseases, Univerisity of California Los Angeles, Los Angeles, CA, USA.
Huang Z; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Boice J; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Huyck S; Centre for Biostatistics, Merck Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International GmbH, Lucerne, Switzerland.; Pokaż więcej
Corporate Authors:: ENCORE investigators
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jun 01; Vol. 11 (6), pp. 680-689.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Crohn Disease/*drug therapy
Gastrointestinal Agents/*adverse effects
Hematologic Diseases/*chemically induced
Infections/*chemically induced
Infliximab/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/adverse effects ; Demyelinating Diseases/chemically induced ; Drug Substitution ; Drug Therapy, Combination/adverse effects ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Infusions, Intravenous/adverse effects ; Lymphoproliferative Disorders/chemically induced ; Male ; Mercaptopurine/adverse effects ; Mesalamine/adverse effects ; Methotrexate/adverse effects ; Middle Aged ; Mortality ; Narcotics/adverse effects ; Prednisone/adverse effects ; Prospective Studies ; Registries ; Risk Factors ; Sulfasalazine/adverse effects ; Time Factors ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial.
Autorzy:: Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada; and Department of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Colombel JF; Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D'Haens G; Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands; and Imelda GI Clinical Research Center, Bonheiden, Belgium.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Rutgeerts P; Division of Gastroenterology, Department of Internal Medicine, University of Leuven, Leuven, Belgium.
Geboes K; Department of Pathology, University of Leuven, Leuven, Belgium.
Petersson J; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Eichner S; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Zhou Q; Data and Statistical Sciences, AbbVie Inc., North Chicago, IL, USA.
Robinson AM; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Read HA; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.
Thakkar R; Global Medical Affairs Gastroenterology, AbbVie Inc., North Chicago, IL, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Apr 01; Vol. 11 (4), pp. 425-434.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Adalimumab/*therapeutic use
Crohn Disease/*drug therapy
Adult ; Colonoscopy ; Crohn Disease/pathology ; Double-Blind Method ; Female ; Humans ; Intestinal Mucosa/pathology ; Male ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Autorzy:: Adedokun OJ; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA .
Xu Z; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Marano CW; Department of Clinical Development Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Strauss R; Department of Translational Medicine Sciences, Janssen Research & Development, LLC, Spring House, PA, USA.
Zhang H; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Johanns J; Department of Clinical Biostatistics, Janssen Research & Development, LLC, Spring House, PA, USA.
Zhou H; Department of Global Clinical Pharmacology, Janssen Research & Development, LLC, Spring House, PA, USA.
Davis HM; Department of Biologics Development Sciences, Janssen Research & Development, LLC, Spring House, PA, USA.
Reinisch W; Department of Gastroenterology, Universitätsklinik für Innere Medizin III, Vienna, Austria & McMaster University, Hamilton, ON, Canada.
Feagan BG; Department of Gastroenterology, Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Rutgeerts P; Department of Gastroenterology, Hospital Gasthuisberg, Leuven, Belgium.
Sandborn WJ; Department of Gastroenterology, University of California San Diego, La Jolla, CA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2017 Jan; Vol. 11 (1), pp. 35-46. Date of Electronic Publication: 2016 Jul 20.
Typ publikacji:: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
Colitis, Ulcerative/*drug therapy
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal/pharmacokinetics ; Colitis, Ulcerative/pathology ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Severity of Illness Index ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.
Autorzy:: Gecse KB; First Department of Medicine, Semmelweis University, Budapest, Hungary .
Sebastian S; Inflammatory Bowel Disease Unit, Hull & East Yorkshire NHS Trust, Hull, UK.
Hertogh Gd; Department of Pathology, University of Leuven, Leuven, Belgium.
Yassin NA; Department of Colorectal Surgery, St Mark's Hospital and Academic Institute, London, UK.
Kotze PG; Colorectal Surgery Unit, Catholic University of Paraná, Curitiba, PR, Brazil.
Reinisch W; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Spinelli A; Colorectal Surgery Unit, Humanitas Research Hospital, Humanitas University, Milan, Italy.
Koutroubakis IE; Department of Gastroenterology, University Hospital Heraklion, Iraklio, Greece.
Katsanos KH; Division of Gastroenterology, Department of Medicine, School of Health Sciences, Ioannina, Greece.
Hart A; Inflammatory Bowel Disease Unit, St Mark's Hospital, London, UK.
van den Brink GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Rogler G; Division of Gastroenterology and Hepatology, University Hospital Zürich, Zürich, Switzerland.
Bemelman WA; Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2016 Jul; Vol. 10 (7), pp. 758-65. Date of Electronic Publication: 2016 Jan 28.
Typ publikacji:: Consensus Development Conference; Journal Article; Systematic Review
MeSH Terms:: Crohn Disease/*physiopathology
Rectal Fistula/*etiology
Crohn Disease/therapy ; Humans ; Magnetic Resonance Imaging ; Outcome Assessment, Health Care/methods ; Rectal Fistula/diagnosis ; Rectal Fistula/pathology ; Rectal Fistula/therapy ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
Autorzy:: Sandborn WJ; Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA .
Colombel JF; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; Department of Medicine, University of Calgary, Calgary, AB, Canada.
Sands BE; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dryden G; Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.
Hébuterne X; Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.
Leong RW; Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.
Bressler B; Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.
Ullman T; Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.
Xu LA; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Luo A; Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2016 Apr; Vol. 10 (4), pp. 418-28. Date of Electronic Publication: 2015 Dec 30.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal/*therapeutic use
Chemokine CXCL10/*antagonists & inhibitors
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Female ; Gastrointestinal Agents/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Remission Induction ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.
Autorzy:: Danese S; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy .
Fiorino G; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
Mary JY; Inserm U1153 - SBIM Hôpital Saint-Louis, Paris, France.
Lakatos PL; 1st Department of Medicine, Semmelweis University, Budapest, Hungary.
D'Haens G; IBD Unit, Gastroenterology, Amsterdam Medical Center, Amsterdam, The Netherlands.
Moja L; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy Unit of Clinical Epidemiology, IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
D'Hoore A; Abdominal Surgery, UZ Leuven, Leuven, Belgium.
Panes J; Gastroenterology Department, Hospital Clinic of Barcelona, IDIPABS, CIBERehd, Barcelona, Spain.
Reinisch W; Medizinische Universität Wien, Klinische Abt. Gastroenterologie & Hepatologie, AKH Wien, Austria.
Sandborn WJ; Division of Gastroenterology, UC San Diego Health System, La Jolla, CA, USA.
Travis SP; Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.
Vermeire S; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Peyrin-Biroulet L; Department of Hepato-Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.
Colombel JF; Department of Gastroenterology, Icahn Medical School at Mount Sinai, New York, NY, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2015 Aug; Vol. 9 (8), pp. 601-6. Date of Electronic Publication: 2015 Apr 23.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Decision Support Techniques*
Health Status Indicators*
Referral and Consultation*
Crohn Disease/*diagnosis
Adult ; Cross-Sectional Studies ; Delayed Diagnosis/prevention & control ; Early Diagnosis ; Humans ; Risk Assessment ; Sensitivity and Specificity ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Reinisch, Walter"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język